Image Credit: STAT News

STAT+: GSK to buy experimental MASH drug for $1.2B upfront

Watchdoq May 14, 2025

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.